Država: Irska
Jezik: angleščina
Source: HPRA (Health Products Regulatory Authority)
CLARITHROMYCIN
Abbott Laboratories Ireland Ltd
250 Milligram
Film Coated Tablet
1989-11-20
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Klacid 250 mg Film-coated Tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Active: Clarithromycin 250.00 mg/tablet For a full list of excipeints, see Section 6.1 3 PHARMACEUTICAL FORM Film-coated tablet Yellow, ovaloid, impressed with the Abbott logo on one side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Clarithromycin is indicated for the treatment of infections due to susceptible organisms. Such infections include: 1. Lower respiratory tract infections (e.g. bronchitis, pneumonia). 2. Upper respiratory tract infections (e.g. pharyngitis, sinusitis). 3. Skin and soft tissue infections (e.g. folliculitis, cellulitis, erysipalis). 4. Disseminated or localised mycobacterial infections due to _Mycobacterium avium _or _Mycobacterium_ _intracellulare_. Localised infections due to _Mycobacterium chelonae, Mycobacterium fortuitum _or _Mycobacterium kansasii._ 5. Clarithromycin is indicated for the prevention of disseminated _Mycobacterium avium _complex infection in HIV - infected patients with CD4 lymphocyte counts less than or equal to 100/mm 3 . 6. Clarithromycin in the presence of acid suppression is indicated for the eradication of _H.pylori_, resulting in decreased recurrence of duodenal ulcer. (See further information). Clarithromycin tablets are indicated in adults and children 12 years and older. Consideration should be given to official guidance on the appropriate use of antibacterial agents FURTHER INFORMATION: _H. pylori _is strongly associated with peptic ulcer disease. Ninety to 100% of patients with duodenal ulcers are infected with this agent. Eradication of _H.pylori _has been shown to markedly reduce the rate of duodenal ulcer recurrence, thereby reducing the need for maintenance anti-secretory therapy. In a well con Preberite celoten dokument